Archive for the ‘American Oriental Bioengineering Inc. AOB’ Category

American Oriental Bioengineering, Inc. (AOB) Reports Profitable Fourth Quarter Of 2009

Tuesday, March 16th, 2010

American Oriental Bioengineering, Inc. reported comprehensive income of $12.3 million, or $0.14 per diluted share, in the fourth quarter of 2009. This was up sharply from the $7.8 million, or $0.10 per diluted share, reported in the same quarter in 2008.

In 2009, the company increased revenue to $296.2 million from $264.6 million in 2008, an increase of 12%. Comprehensive income fell over the same time period, however, from $62.8 million, or $0.61 per diluted share, to $42.7 million, or $0.53 per diluted share, in 2009.

“We are very pleased with our 2009 performance despite the increasingly challenging economic environment worldwide and China’s rapidly changing regulatory environment. In 2009, we expanded our product portfolio, strengthened our leading brands and diversified our operations,” said Tony Liu, the CEO of American Oriental Bioengineering, Inc.

American Oriental Bioengineering, Inc. is a pharmaceutical company that manufactures and sells both prescription and over the counter products serving mostly the Chinese market. The company was founded in 1970 and maintains offices in the United States and China.

Major products of American Oriental Bioengineering, Inc. include the Jinji Series of products, Shuanghuanglian Injection Powder, the Cease Enuresis Soft Gel and Patch, YuYeQingHuo capsules and Shedanchan beiye.

Let us hear your thoughts below:

American Oriental Bioengineering, Inc (AOB) is Thriving in Today’s Sluggish World Economy

Monday, March 9th, 2009

American Oriental Bioengineering, Inc, (NYSE:AOB) announced today that its fourth quarter 2008 revenues were up a whopping 68% to $96.3 million. Net income for the same period was up 43% to $21.7 million. The good news reflects the continued demand for the company’s pharmaceutical and nutritional products in the Chinese marketplace.

American Oriental, based in China, is engaged in the development and production of plant based products, both pharmaceutical and nutritional. The products are produced from the leaves and roots of various plants. In the case of PBPs (Plant Based Pharmaceuticals), they are used to treat illnesses or associated symptoms and are available in China by prescription and over-the-counter. PBNs (Plant Based Nutraceuticals) are also produced from plant leaves and roots, but are used as preventatives and for general health, and are all sold over-the-counter.

Tony Liu, company Chairman and CEO, commented on the company’s success, in spite of the overall economy, and the focus for the future: “In 2008, we strengthened our leading brands, enhanced our product portfolio, and diversified our operations in a way that lends flexibility to our business model, so that we can navigate China’s rapidly changing regulatory environment. We achieved these successes despite the increasingly challenging economic environment worldwide, and we are cautiously optimistic that China’s healthcare industry remains somewhat insulated from the global economic crisis. Going into 2009 and 2010, we’ll continue to strengthen our core competencies in production, sales and marketing and distribution reach, as well as focus on R&D efforts and our infrastructure, to ensure that we are well-prepared to capitalize on the many opportunities we see in China’s healthcare sector.”

American Oriental has seven pharmaceutical manufacturers, two health food manufacturing plants, one plant based pharmaceutical research center, a commercial company, and a marketing and sales headquarters. It has established management, manufacturing, financial, and information headquarters in New York, and in Shenzhen, Harbin and Hong Kong in China.

The company states that it has a simple but far-reaching goal to be the perpetual global leader in modern plant-based products.

Let us hear your thoughts below:

American Oriental Bioengineering Inc. (AOB) is “One to Watch”

Thursday, October 9th, 2008

Today, we are adding American Oriental Bioengineering Inc. to our China “One’s to Watch” list. Together with its subsidiaries, the company engages in the development, manufacture, and commercialization of a range of pharmaceutical and healthcare products. Based in Shenzhen, China, the company has a market capitalization of approximately $400 million.

The company provides more than 30 over-the-counter type drugs, and conducts its own research, development, production, and distribution of more than 40 pharmaceutical products. Currently all of their products are approved by the Chinese State Food and Drug Administration (SFDA). In the pipeline, American Oriental has over 400 SFDA approved products that have yet to be commercially launched.

American Oriental is well positioned with $144.47 million in cash and only $10.78 million in debt. Historical sales have grown over 70% annually while earnings per share sustain a 40%+ growth rate. Analysts have shown strong support as four rate the stock a “Strong Buy” and one calls it a “Buy”. Insiders have also shown their positive outlook for the company by holding 21% of the outstanding shares.

With the current economic turbulence, it is unlikely the company will be able to maintain its tremendous growth rate in the near term, but investors have already discounted this fact by valuing the company at a Forward P/E of just 5.49. In view of the major discount, excellent cash position, and historical growth performance, American Oriental is now a “One to Watch” at QualityStocks.

Let us hear your thoughts: American Oriental Bioengineering Inc. Message Board